This week's roundup of Houston innovators includes Niloufar Molavi of Central Houston Inc., Dan Purvis of Velentium, and Chris Staffel of Goose Capital. Courtesy photos

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to three innovators — each either new to their role or with a bit of acquistion news.

Niloufar Molavi, board chair at Central Houston Inc.

Niloufar Molavi will lead Central Houston Inc.'s board this year — and she's got fostering innovation on her to-do list. Photo courtesy of CHI

Last week, Nilofar Molavi assumed the role of board chair for Central Houston. She leads PwC's Global energy practice and has served on the CHI board since 2011 and chairs the organization's innovation committee. CHI was among the partners behind the Downtown Launchpad, a 17,000-square-foot innovation hub, which had its grand opening last fall.

"With the fall 2020 opening of Downtown Launchpad, we have deepened our investment in innovation, which we hope will garner long-term results and economic vitality for downtown as well as the Houston region at large," she continues. "We look forward to developing bridge programs with area universities and organizations and leveraging existing resources to bring more high-tech prospects to our central city." Read more.

Dan Purvis, CEO of Velentium

A Houston company has made a strategic acquisition. Photo courtesy of Velentium

Houston-based Velentium, which specializes in the design and manufacturing of medical devices announced that it has acquired Texas company Oasis Testing, a designer of automated test systems for the energy and manufacturing industries.

"Despite the immense challenges facing the business community in 2020, last year was a monumental year of growth for our firm, and we're pleased to start 2021 building upon our world-class team of technical experts," says Dan Purvis, CEO of Velentium, in a news release. "Oasis Testing has been a trusted partner for the last five years and shares in our commitment to solving clients' most complex challenges to change lives for a better world. We're incredibly excited to welcome them to the Velentium family and expand our business more deeply into energy and manufacturing."

Purvis will lead the new combined company as CEO. Read more.

Chris Staffel, managing director at Goose Capital

Goose Capital recently named its new managing director. Photo courtesy of Chris Staffel

Houston-based investment group Goose Capital Inc. named Chris Staffel as managing director — along with Jeff Smisek as the firm's president and Jay Collins as chair of the board of directors.

A serial entrepreneur and investor in over 30 startups, Staffel joins Goose to lead day-to-day operations and drive new investment opportunities.

"It is an honor to join the team at Goose Capital and work alongside experienced industry leaders," Staffel says in the release. "I look forward to leveraging my entrepreneurial experience to help the start-ups in which we invest, while strategically identifying early stage investment opportunities." Read more.

Niloufar Molavi will lead Central Houston Inc.'s board this year — and she's got fostering innovation on her to-do list. Photo courtesy of CHI

Houston organization names new leader to focus on innovation and economic development

now in charge

An organization that promotes redevelopment and revitalization in Houston has named its new board leader for 2021.

Niloufar Molavi, partner at PwC US, has assumed Central Houston Inc.'s board leadership role effective January 8. Molavi, who leads PwC's Global energy practice, has served on the CHI board since 2011 and chairs the organization's innovation committee.

"Over more than a decade serving on the CHI board, I have witnessed first-hand the major changes that the organization has affected in downtown," Molavi says in a news release. "Among our 2021 priorities is to continue to foster the growth of the innovation sector."

In October, CHI — along with its partners, Amegy Bank and the Downtown Redevelopment Authority — celebrated the grand opening of the Downtown Launchpad, a 17,000-square-foot innovation hub located on the 10th floor of Amegy on Main (1801 Main Street). The hub is home to Houston's MassChallenge Texas and gener8tor accelerators and global nonprofit incubator Impact Hub Houston. The Cannon Houston is the operation partner for the space.

"With the fall 2020 opening of Downtown Launchpad, we have deepened our investment in innovation, which we hope will garner long-term results and economic vitality for downtown as well as the Houston region at large," she continues. "We look forward to developing bridge programs with area universities and organizations and leveraging existing resources to bring more high-tech prospects to our central city."

Molavi, as board chair, will focus on near-term and long term strategic priorities for CHI, which include the region's economic recovery following the pandemic, improving transportation, further developing the innovation ecosystem, recruiting new employers to downtown, and more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”